EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial

Steven Perrin iD, Shafeeq Ladha, Nicholas Maragakis, Michael H Rivner iD, Jonathan Katz, Angela Genge, Nicholas Olney, Dale Lange, Daragh Heitzman, Cynthia Bodkin, Omar Jawdat, Namita A Goyal iD und 4 weitere

PLOS Medicine · 2024

DOI: 10.1371/journal.pmed.1004469 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift PLOS Medicine, 2024. Verfasst von Steven Perrin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Eledon Pharmaceuticals, Irvine, California, United States of America. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eledon Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The interaction of CD40L and its receptor CD40 on activated T cells and B cells respectively control pro-inflammatory activation in the pathophysiology of autoimmunity and transplant rejection. Previous studies have implicated signaling pathways involving CD40L (interchangeably referred to as CD154), as well as adaptive and innate immune cell activation, in the induction of neuroinflammation in neurodegenerative diseases. This study aimed to assess the safety, tolerability, and impact on pro-inflammatory biomarker profiles of an anti CD40L antibody, tegoprubart, in individuals with amyotrophic lateral sclerosis (ALS). Methods and findings In this multicenter dose-escalating open-label Phase 2A study, 54 participants with a diagnosis of ALS received 6 infusions of tegoprubart administered intravenously every 2 weeks. The study was comprised of 4 dose cohorts: 1 mg/kg, 2 mg/kg, 4 mg/kg, and 8 mg/kg. The primary endpoint of the study was safety and tolerability. Exploratory endpoints assessed the pharmacokinetics of tegoprubart as well as anti-drug antibody (ADA) responses, changes in disease progression utilizing the Revised ALS Functional Rating Scale (ALSFRS-R), CD154 target engagement, changes in pro-inflammatory biomarkers, and neurofilament light chain (NFL). Seventy subjects were screened, and 54 subjects were enrolled in the study. Forty-nine of 54 subjects completed the study (90.7%) receiving all 6 infusions of tegoprubart and completing their final follow-up visit. The most common treatment emergent adverse events (TEAEs) overall (>10%) were fatigue (25.9%), falls (22.2%), headaches (20.4%), and muscle spasms (11.1%). Mean tegoprubart plasma concentrations increased proportionally with increasing dose with a half-life of approximately 24 days. ADA titers were low and circulating levels of tegoprubart were as predicted for all cohorts. Tegoprubart demonstrated dose dependent target engagement associated and a reduction in 18 pro-inflammatory biomarkers in circulation.

Conclusions

Tegoprubart appeared to be safe and well tolerated in adults with ALS demonstrating dose-dependent reduction in pro-inflammatory chemokines and cytokines associated with ALS. These results warrant further clinical studies with sufficient power and duration to assess clinical outcomes as a potential treatment for adults with ALS.

Trial registration

Clintrials.gov ID: NCT04322149 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisAdultAgedFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkersCD40 LigandDisease ProgressionDose-Response Relationship, DrugNeurofilament ProteinsPyrazinesTreatment OutcomeImidazoles

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkersCD40 LigandCK-2017357Neurofilament ProteinsPyrazinesImidazoles

Autor:innen und Institutionen

  • Eledon Pharmaceuticals, Irvine, California, United States of America.
  • Departments of Neurology and Translational Neuroscience, St. Joseph's Hospital and Medical Center and Barrow Neurological Institute, Phoenix, Arizona, United States of America.
  • Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
  • Department of Neurology, Augusta University, Augusta, Georgia, United States of America.
  • California Pacific Medical Center Research Institute and Forbes Norris MDA/ALS Research and Treatment Center, San Francisco, California, United States of America.
  • Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada.

ORCID-Profile: Steven Perrin, Michael H Rivner, Namita A Goyal, Jeffrey D Bornstein, Sabrina Paganoni

Förderung

  • Eledon Pharmaceuticals

Zitieren

APA

Perrin, S., Ladha, S., Maragakis, N., Rivner, M. H., Katz, J., Genge, A., Olney, N., Lange, D., Heitzman, D., Bodkin, C., Jawdat, O., Goyal, N. A., Bornstein, J. D., Mak, C., Appel, S. H., & Paganoni, S. (2024). Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004469

Vancouver

Perrin S, Ladha S, Maragakis N, Rivner MH, Katz J, Genge A, et al. Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial. PLOS Medicine. 2024. doi:10.1371/journal.pmed.1004469

BibTeX
@article{Perrin2024,
  author = {Perrin, Steven and Ladha, Shafeeq and Maragakis, Nicholas and Rivner, Michael H and Katz, Jonathan and Genge, Angela and Olney, Nicholas and Lange, Dale and Heitzman, Daragh and Bodkin, Cynthia and Jawdat, Omar and Goyal, Namita A and Bornstein, Jeffrey D and Mak, Carmen and Appel, Stanley H and Paganoni, Sabrina},
  title = {Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial},
  journal = {PLOS Medicine},
  year = {2024},
  doi = {10.1371/journal.pmed.1004469}
}
Kostenlos starten →